Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

B-cell Non Hodgkin Lymphoma · Chronic Lymphocytic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States